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ABSTRACT
Back ground and the purpose of study: Sumatriptan succinate is a Serotonin 5- HT1 receptor 
agonist, used in treatment of migraine. It is absorbed rapidly but incompletely when given 
orally and undergoes first - pass metabolism, resulting in a low absolute bioavailability of about 
15%. The aim of this work was to design mucoadhesive bilayered buccal tablets of sumatriptan 
succinate to improve its bioavailability.
Methods:  Mucoadhesive  polymers  carbopol  934  (Carbopol),  HPMC  K4M,  HPMC  K15M 
along with ethyl cellulose as an impermeable backing layer were used for the preparation of 
mucoadhesive bilayered tablets . In vivo  bioavailability studies was also conducted in rabbits 
for optimized formulation using oral solution of sumatriptan succinate as standard.
Results: Bilayered buccal tablets (BBT) containing the mixture of Carbopol and HPMC K4M 
in the ratio 1:1 (T1) had the maximum percentage of in vitro drug release within 6 hrs. The 
optimized formulation (T1) followed non-Fickian release mechanism. The percentage relative 
bioavailability of sumatriptan succinate from selected bilayered buccal tablets (T1) was found 
to be 140.78%.
Conclusions: Bilayered buccal tablets of sumatriptan succinate was successfully prepared with 
improved bioavailability.
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INTRODUCTION
Buccal delivery of drugs which exhibit a low oral 
bioavailability is a useful method for increasing 
bioavailability  (1)  and  provides  an  attractive 
alternative to the oral route of drug administration, 
particularly in overcoming deficiencies associated 
with the latter mode of dosing. Problems such as 
high first-pass metabolism, and drug degradation 
in  the  harsh  gastrointestinal  environment,  can 
be  circumvented  by  administration  of  the  drug 
via  the  buccal  route  (2).  This  route  has  been 
used successfully for the systemic delivery of a 
number of drug candidates (3). Moreover, buccal 
drug  delivery  offers  a  safe  and  easy  method  of 
drug utilization, because drug absorption can be 
promptly  terminated  in  the  case  of  toxicity  by 
removing the dosage form from the buccal cavity. 
It is also an alternative route to administer drugs 
to  patients  who  are  unable  to  be  dosed  orally. 
Therefore,  adhesive  mucosal  dosage  forms  are 
suggested for buccal delivery, including adhesive 
tablets (4), adhesive gels (5) and adhesive patches 
(3).
Sumatriptan  succinate  is  5-HT1receptor  agonist 
used in the treatment of migraine. However, since 
a  substantial  proportion  of  patients  suffer  from 
severe  nausea  or  vomiting  during  their  migraine 
attacks, and low oral bioavailability (15%) because 
of high first-pass metabolism, may be oral treatment 
unsatisfactory. Nasal and subcutaneous routes have 
their own limitations, like lower retention time for 
nasal solution and inability of self administration for 
injectables respectively (6).
In the treatment migraine, therapy requires constant 
levels  of  the  drug  in  the  blood  for  an  extended 
period, which can be achieved by design of buccal 
drug delivery system to deliver the drug via oral 
buccal mucosa.
The  aim  of  this  investigation  was  to  determine 
pharmacokinetics  of  sumatriptan  succinate  from 
administered as BBT formulation of a dose of 10 mg. 
MATERIAL AND METHODS
Sumatriptan  succinate  (Aurobindo  Pharma  Ltd, 
Medak) aspartame (Strides Arco Labs, Bangalore 
India) HPMC K4M and HPMC K15M (Colorcon 
Pvt  limited,  Goa)  and  Carbopol  934P  (Mumbai 
India)  were  obtained  as  gift  sample.  All  other 
chemicals and reagents used in the work were of 
analytical grades. 
224Compatibility studies
Compatibility  studies  of  drug  and  polymers  were 
studied  using  Fourier  Transform  Infrared  (FTIR) 
spectroscopy and Differential scanning calorimetry 
(DSC)  techniques.  FTIR  Spectrum  was  recorded 
between 600-4000 cm-1 using Bruker Tensor(ATR). 
DSC  thermograms  were  recorded  at  a  standard 
heating rate of 10ºC/min over a temperature range 
50-400 ºC using DSC-60 Shimadzu (Japan). Samples 
were treated under nitrogen atmosphere in order to 
eliminate oxidative and pyrolytic effects.
Preparation of BBT of sumatriptan succinate
Various batches of BBT were prepared by changing 
the  ratio  of  carbopol,  HPMC  K4M,  and  HPMC 
K15M. The drug-polymer combination was mixed 
and triturated for 15min (Table 1) in a glass mortar 
to  obtain  homogeneous  mixture.  The  powder 
mixture equivalent to 131mg was then compressed 
directly using an 8mm diameter die in a single-
stroke multistation tablet machine (Karnavati mini 
press,  India).  Upper  punch  was  raised  and  the 
backing layer of ethyl cellulose was placed on the 
above compact. Then 2 layers were compressed into 
a mucoadhesive bilayer tablet with a total weight of 
151 mg/tablet (7).
Evaluation of physical properties of BBT 
The thickness, hardness, friability, weight uniformity 
and drug content uniformity were determined as per 
the procedure of Indian Pharmacopoeia (8).
Surface pH
The BBT were allowed to swell at 37±0.5°C for 2hrs 
in 40ml phosphate buffer (pH of 6.8) and surface pH 
of  swollen  BBT’s  was  measured  using  pH  paper 
(9). 
Swelling study
Swelling  properties  of  tablets  were  evaluated  by 
determination of the percentage of hydration (10) 
and calculated according to the following equation:
 
Swelling index =
(W2–W1)
× 100
W2
Ex Vivo mucoadhesive strength and mucoadhesion 
Time
Ex vivo  adhesion strength is the force in grams 
required  to  pull  out  a  tablet  from  sheep  buccal 
mucosa (11). Time required to detach or erode BBT 
from the sheep buccal mucosa was taken as ex-vivo 
mucoadhesion time in hours (12). 
In vitro dissolution studies 
The  United  States  Pharmacopoeia  (USP)  XXIII 
method  was  used  to  study  the  drug  release  from 
the tablets (13). Each BBT tablet was attached on 
a glass plate with cyanoacrylate adhesive. The glass 
plate  was  then  placed  in  a  dissolution  tester. The 
experiments were performed at 37±0.5°C using the 
paddle method at 50 rpm with 500 ml of phosphate 
buffer of pH 6.8 as a dissolution medium. Samples 
equivalent to 5 ml was withdrawn for every one hour, 
filtered and analyzed at 227 nm using UV-Visible 
spectrophotometer (Shimadzu, Kyoto-1700, Japan).
Release  data  were  fitted  to  various  mathematical 
models Korsmeyer-Peppa’s [Eq 1](14), zero order 
[Eq 2] (15) and Higuchi release models [Eq 3](16) in 
order determine the release mechanism from BBT.
In vivo  study 
The experimental protocol for all In vivo  studies was 
approved by institutional animal ethical committee 
(997/c/06/ CPCSEA).
White male rabbits were fasted for 24 hrs before 
drug  administration  and  sedated  using  ketamine: 
lignocaine (1:5) mixture. A bioadhesive tablet was 
fixed in the buccal position of the oral cavity. Blood 
samples were withdrawn from the ear vein in the 
eppendorf tubes containing sodium EDTA of 10µl 
(10% w/v) at time interval of 0.5-12 and 24hrs, 
analysed by LC-MS/MS. For oral administration, 
10mg  doses  in  25ml  of  aqueous  solution  were 
administered by a stomach tube (17).
Estimation  of  sumatriptan  succinate  from  plasma 
samples
Centrifuge a mixture of 100 µl plasma sample and 
600 µl of acetonitrile at 13000 rpm for 4min and 
inject  10µl  supernatant  solution  at  a  flow  rate  of 
1.2 ml/min and at 25°C with mobile phase consists 
of 60% formic acid in water (0.05%): formic acid 
in acetonitrile (0.05%) and telmisartan as internal 
standard.  The  ions  monitored  using  multiple 
reactions  monitoring  (MRM),  were  m/z  296.1→
251.1  for  sumatriptan  succinate  and  m/z  515.2→
497.3  for  telmisartan.  Pharmacokinetic  data  were 
prepared by using software Sciex Analyst version 
1.4.2.
RESULTS AND DISCUSSIONS
Drug polymer compatibility studies using FTIR and 
DSC
FTIR  studies  revealed  that  the  characteristic 
absorbance bands of various functional groups of 
sumatriptan  succinate  were  found  in  the  vicinity 
of  standard  absorbance  range  (Fig  1).  Hence  the 
FTIR studies indicated that there was no interaction 
between drugs and polymers under study.
DSC  studies  revealed  that  the  drug  exhibit  sharp 
melting endotherm at 170.30°C and thermograms of 
the physical mixture of sumatriptan succinate with 
polymers exhibited endothermic peak in the vicinity 
of its melting point range, indicates absence of any 
drug-polymer interactions (Fig 2).
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Physical properties of BBT
The average weight, thickness, hardness and friability 
were found within the limits of IP (8). Whereas drug 
content (%) of all formulations were in the range of 
99.24-97.89%. The surface pH of BBT was found 
to be 6-7 which indicates that there will not be any 
local irritation to the buccal mucosa.
Swelling  index  decreased  by  decrease  in  the 
concentration  of  carbopol  which  is  evident  from 
the determined mean swelling values of 95%, 80% 
and 71% after 2 hrs for the formulation T1-T3. In 
the case of formulations T4-T6 the mean swelling 
values were 73%, 61%, and 62% after 2 hrs, the 
swelling indices of the tablets with carbopol and 
HPMC  increased  by  increase  in  the  amounts  of 
carbopol.  
Ex-Vivo  bioadhesive  strength  and  Mucoadhesion 
Time
The  tablets  with  the  HPMC  K4M,  carbopol  had 
bioadhesive  strength  between  17.5-21g  and  with 
HPMC K15M, carbopol had bioadhesive strength 
15.6-20.4g  (Table  2).  The  bioadhesive  strength 
exhibited  by  the  HPMC  K4M  tablets  can  be 
considered satisfactory for their maintainance in the 
oral cavity
The  mucoadhesive  times  on  sheep  buccal  mucosa 
were  7-12  hrs.  The  increase  in  concentration  of 
carbopol in series from formulation T1-T6, showed 
a gradual rise in mucoadhesion time, while HPMC 
K4M, HPMC K15M were also a good mucoadhesive 
polymers, showed a decrease in mucoadhesion time 
(Table 2).
In vitro dissolution studies
Release of drug from the BBT varied according to the 
type and ratio of matrix-forming polymer. Carbopol 
has  excellent  mucoadhesive,  gelling  properties 
and  also  helps  in  sustaining  effect.  Combination 
of carbopol and HPMC are hydrophilic swellable 
polymer matrices, which are able to form a viscous 
gel layer which controls the drug release via diffusion 
through the gel and erosion of gel barrier (18).
The cumulative drug release at the end of 6th hour 
for formulations T1 and T4 were 67.73%, 64.11%, 
respectively (Fig 3). The results indicate that the rate 
of drug release was higher for T1 formulation which 
may be due to rapid ionization of carbopol (19). The 
rate  of  drug  release  decreased  by  increase  in  the 
concentration of HPMC K4M which may be due to 
the increase in viscosity produced by the gelling of 
the hydrophilic polymer HPMC K4M. 
For  non-Fickian  release,  the  value  of  n  falls 
between 0.5 and 1.0, while in the case of Fickian 
diffusion,  n=0.5;  for  zero  order  release  (case  II 
transport), n=1; and for supercase II transport, n 
is greater than 1. All of these formulations exerted 
non-fickian  diffusion  mechanism  with  n  value 
Formulation 
code
Sumatriptan 
succinate (mg)
HPMC K4M 
(mg)
HPMC K15M 
(mg)
Carbopol 934P 
(mg)
Aspartame
(mg)
MCC
(mg)
Magnesium 
stearate (mg)
Ethyl
cellulose (mg)
T1 10 25 75 1 18 2 20
T2 10 50 50 1 18 2 20
T3 10 75 25 1 18 2 20
T4 10 25 75 1 18 2 20
T5 10 50 50 1 18 2 20
T6 10 75 25 1 18 2 20
Table 1. Ingredients of bilayered buccal tablets of sumatriptan succinate.
Formulation 
code
Thickness
(mm)*
Average weight of 
tablet (mg)±SD
Hardness 
(kg/cm2)±SD
Friability 
(%)*
Drug content 
(%)±SD
Surface 
pH*
Mucoadhesion 
time (h)±SD
Mucoadhesion 
strength (g)±SD
T1 3.12 151±1.43 5.2±0.14 0.463 98.74±1.74 6 12.0±1.25 21.0±1.32
T2 3.12 151±1.18 5.2±0.17 0.453 97.85±1.35 6 10 .0±0.50 19.0±0.20
T3 3.11 150±1.72 5.4±0.18 0.411 98.00±2.20 7 09.0 ±1.30 17.5±0.97
T4 3.05 151±1.26 5.4±0.23 0.372 98.86±3.40 6 12.0±1.35 20.4±0.60
T5 3.05 149±1.56 5.4±0.11 0.449 99.01±2.01 6 10.0±0.30 17.5±1.45
T6 3.04 150±1.21 5.6±0.16 0.403 98.79±1.92 7 09.0±0.40 15.6±1.90
Average of three determinations±SD
* Average of three determinations
Table 2. Physicochemical properties of bilayered buccal tablets of sumatriptan succinate.Shivanand et al / DARU 2011 19 (3) 224-230 227
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Figure 1. FTIR Spectra of formulations of Sumatriptan succinate A. Sumatriptan succinate, B. Sumatriptan succinate + HPMCK4M + 
Carbopol 394, C. Sumatriptan succinate + HPMCK15M + Carbopol 394
Formulation code
Korsmeyer Peppa’s Zero order First order Higuchi
t50% (h)
K R2 n K R2 K R2 K R2
T1 15.24 0.997 0.817 10.86 0.992 -0.17733 0.986 27.30 0.949 4.20
T2 20.23 0.984 0.606 9.726 0.964 -0.15430 0.980 25.15 0.976 4.60
T3 17.90 0.993 0.644 9.187 0.970 -0.13818 0.991 23.71 0.978 4.70
T4 15.24 0.994 0.788 10.44 0.993 -0.16582 0.990 26.23 0.948 4.45
T5 16.33 0.964 0.681 9.409 0.984 -0.14279 0.979 23.75 0.948 4.90
T6 16.40 0.992 0.638 8.086 0.957 -0.11515 0.987 21.10 0.987 5.80
Table 3. Kinetic analyse of the release of bilayered buccal tablets of sumatriptan succinate.Bilayered buccal tablets of sumatriptan succinate 228
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figure 2. DSC Thermograms of formulations of Sumatriptan succinate. A. Sumatriptan succinate, B. Sumatriptan succinate + HPMCK4M + 
Carbopol 394, C. Sumatriptan succinate + HPMCK15M + Carbopol 394.
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fig 3: Dissolution profiles of bilayered buccal tablets of sumatriptan succinate             (A) 
HPMC K4M:  Carbopol 934P, (B)  HPMC  K15M: Carbopol  934P (Mean  ±  SD of  three 
determinations) 
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HPMC K4M:  Carbopol 934P, (B)  HPMC  K15M: Carbopol  934P (Mean  ±  SD of  three 
determinations) 
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Figure 3. Dissolution profiles of bilayered buccal tablets of sumatriptan succinate. (A) HPMC K4M: Carbopol 934P, (B) HPMC K15M: 
Carbopol 934P (Mean ± SD of three determinations).Shivanand et al / DARU 2011 19 (3) 224-230 229


fig-4: Plasma concentration time profile of sumatriptan succinate after oral and buccal 
administration in rabbits (Mean ± SD of three determinations) 
Table-4: Comparative pharmacokinetics parameters of sumatriptan succinate after oral 
and buccal administration in rabbits 
Pharmacokinetic 
parameter 
Pure drug  T1
Ke (h
-1) 1.91 1.46
Cmax  (ng/ml)   482.20 ± 22.5  386.00 ± 15.80 
Tmax (h) 2.0 2.0
AUC (0-24) (ng.h/ml)  1199.64 ±150.60  1690.69 ± 90.16 
AUC(0-)
(ng.h/ml)  
1200.90 ± 150.60  1693.90 ± 91.50 
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figure 4. Plasma concentration time profile of sumatriptan succinate after oral and buccal administration in rabbits (Mean ± SD of three 
determinations).
Pharmacokinetic parameter  Pure drug  T1 
Ke (h-1) 1.91  1.46 
Cmax  (ng/ml)  482.20±22.5 386.00±15.80
Tmax (h) 2.0  2.0 
AUC (0-24) (ng.h/ml)  1199.64±150.60 1690.69±90.16
AUC(0-∞)  (ng.h/ml)  1200.90±150.60 1693.90±91.50
Table 4. Comparative pharmacokinetics parameters of sumatriptan succinate after oral and buccal administration in rabbits.
varied from 0.604-0.817. This is an indicative of 
both  diffusion  and  chain  relaxation  mechanism 
which is a prerequisite for sustained drug release 
effect. Based on these results T1 formulation was 
selected for further studies. 
In vivo bioavailability studies in rabbits
The  mean  plasma  concentration  of  sumatriptan 
succinate at different time intervals following the 
application of BBT and after oral administration of 
solution in rabbits is shown in (Fig. 4).
Following  oral  administration  of  sumatriptan 
succinate  (10  mg)  in  solution  form,  average 
maximum serum concentration (Cmax) 482.20±22.5 
ng/ml was achieved after 2 hrs and the area under 
the  serum  concentration-time  curve  (AUC  (0-∞)) 
after oral dosing was found to be 1200.90±150.60 
ng/ml. After administration of T1 formulation the 
drug levels in serum were detectable till 12 hrs with 
Cmax
 386.00±15.80 ng/ml achieved 2 hrs after dosing 
and  the  AUC(0-∞) following  buccal  administration 
of  sumatriptan  succinate  1693.90±91.50  ng/ml. 
Relative  bioavailability  of  sumatriptan  succinate 
following  buccal  administration  was  found  to  be 
140.78% which could be due to reduced first pass 
metabolism,  when  it  is  administered  via  buccal 
route.
CONCLUSIONS
Developed  BBT  of  sumatriptan  succinate  may 
overcome the disadvantage of poor and erratic oral 
bioavailability of sumatriptan succinate associated 
with  marketed  formulations.  This  increased 
predictable  availability  of  sumatriptan  succinate 
from designed formulation may result in substantial 
dose reduction.
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